Literature DB >> 2816966

Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients.

R A Robbins1, J Linder, M G Stahl, A B Thompson, W Haire, A Kessinger, J O Armitage, M Arneson, G Woods, W P Vaughan.   

Abstract

PURPOSE: The purpose of our work was to evaluate pulmonary complications in autologous bone marrow transplant recipients. PATIENTS AND METHODS: A total of 141 consecutive autologous bone marrow transplant recipients were evaluated. In 29 patients, a clinical syndrome characterized by progressive dyspnea, hypoxia, cough, diffuse consolidation on chest roentgenography, and characteristic bronchoalveolar lavage findings developed over one to seven days.
RESULTS: In 29 patients, bronchoalveolar lavage performed by sequential instillation and aspiration of 20-ml aliquots of normal saline resulted in recovered lavage fluid that became progressively bloodier with each recovered aliquot. Autopsy and bronchoalveolar lavage in these patients revealed no pathogens that accounted for the clinical findings. Since the later aliquots sample predominantly alveolar material, this syndrome was termed diffuse alveolar hemorrhage (DAH). DAH was associated with a high inpatient mortality rate (23 of 29 died versus 14 of 112 without DAH, p less than 0.001) and was associated with age over 40 years, solid malignancies, high fevers, severe mucositis, white blood cell recovery, and renal insufficiency (p less than 0.05, compared with patients without DAH). However, DAH was not associated with prolonged prothrombin or partial thromboplastin times or decreased platelet counts compared with patients without DAH.
CONCLUSION: DAH is a frequent cause of respiratory compromise and a major cause of mortality in autologous bone marrow transplant recipients.

Entities:  

Mesh:

Year:  1989        PMID: 2816966     DOI: 10.1016/s0002-9343(89)80606-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  21 in total

1.  Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures.

Authors:  A Rañó; C Agustí; P Jimenez; J Angrill; N Benito; C Danés; J González; M Rovira; T Pumarola; A Moreno; A Torres
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

2.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.

Authors:  Akiko M Saito; Corey Cutler; David Zahrieh; Robert J Soiffer; Vincent T Ho; Edwin P Alyea; John Koreth; Joseph H Antin; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

3.  Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.

Authors:  Jason M Elinoff; Ulas Bagci; Brad Moriyama; Jennifer L Dreiling; Brent Foster; Nicole J Gormley; Rachel B Salit; Rongman Cai; Junfeng Sun; Andrea Beri; Debra J Reda; Farhad Fakhrejahani; Minoo Battiwalla; Kristin Baird; Jennifer M Cuellar-Rodriguez; Elizabeth M Kang; Stephen Z Pavletic; Dan H Fowler; A John Barrett; Jay N Lozier; David E Kleiner; Daniel J Mollura; Richard W Childs; Anthony F Suffredini
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-20       Impact factor: 5.742

Review 4.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

Review 5.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

6.  Diffuse pulmonary alveolar hemorrhage after allogeneic bone marrow transplantation.

Authors:  I Schmidt-Wolf; R Schwerdtfeger; N Schwella; J Gallardo; H J Schmid; D Huhn; W Siegert
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

7.  Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage.

Authors:  N K Rathi; A R Tanner; A Dinh; W Dong; L Feng; J Ensor; S K Wallace; S A Haque; G Rondon; K J Price; U Popat; J L Nates
Journal:  Bone Marrow Transplant       Date:  2014-12-22       Impact factor: 5.483

8.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

9.  Pulmonary complications after hematopoietic stem cell transplantation.

Authors:  Do Hyoung Lim; Jeeyun Lee; Hong Ghi Lee; Byeong-Bae Park; Kyong Ran Peck; Won Sup Oh; Sang Hoon Ji; Se-Hoon Lee; Joon Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Keunchil Park
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

Review 10.  Intensive care and oncology.

Authors:  J P Sculier
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.